UCB moves to buy Candid Therapeutics for up to $2.2B: full analysis
UCB is making another sizable immunology bet, agreeing to acquire Candid Therapeutics for up to $2.2 billion in a deal centered on cizutamig, a BCMAxCD3 bispecific T-cell engager for autoimmune disease. The Belgian drugmaker said the transaction includes $2.0 billion upfront and up to $200 million in milestone payments, with closing expected in late Q2 or early Q3 2026 pending antitrust clearance and customary conditions. (ucb.com)
The move comes just two months after Candid announced plans to go public through a reverse merger with Rallybio, backed by more than $505 million in concurrent financing expected to fund operations through 2030. At that time, Candid positioned itself as a clinical-stage company with one of the more advanced autoimmune T-cell engager portfolios, and said it planned phase 2 starts for cizutamig in myasthenia gravis and interstitial lung disease secondary to rheumatologic diseases. UCB’s bid effectively interrupts that path and folds Candid into a larger immunology franchise instead. (investors.rallybio.com)
At the center of the acquisition is cizutamig, which UCB describes as a potential best-in-class BCMA-targeting T-cell engager for autoimmune disease. The company said the bispecific antibody is designed to direct T cells against BCMA-expressing plasma cells and B cells while limiting cytokine release, a key safety concern for the class. According to UCB, the drug has already been evaluated in more than 100 patients across multiple myeloma and autoimmune disease, and is now in multiple clinical studies spanning more than 10 autoimmune indications. One listed trial is a phase 1 open-label study in refractory seropositive rheumatoid arthritis. (ucb.com)
The acquisition also fits a broader pattern. UCB said the Candid purchase builds on its recently announced Antengene transaction, which gave it worldwide rights to ATG-201, a CD19/CD3 bispecific T-cell engager for autoimmune disease. Taken together, the two deals expand UCB’s reach across multiple B-cell targets and suggest a deliberate platform strategy around next-generation biologics that aim for deeper, potentially more durable immune intervention. (ucb.com)
Industry coverage has framed the deal as part of a wider race to develop therapies that can “reset” the immune system rather than broadly suppress it over time. BioPharma Dive noted growing competition in autoimmune T-cell engagers and pointed to interest from other large drugmakers in adjacent approaches. Earlier reporting on Candid’s 2024 launch also highlighted investor enthusiasm for bispecifics as a potentially more convenient and scalable alternative to cell therapy in autoimmune disease. (biopharmadive.com)
Why it matters: For veterinary professionals, this deal is worth watching less for any immediate clinical impact in animal health and more for what it says about the direction of immunology innovation. The underlying ideas, selective depletion of disease-driving B-cell or plasma-cell populations, engineering around cytokine-release risk, and pursuit of longer remissions instead of continuous suppression, are highly relevant across species. Companion animal medicine still has limited access to advanced immune-targeted biologics, but the translational playbook is getting clearer as human biopharma invests heavily in these mechanisms. (ucb.com)
There’s also a business signal here. Candid launched in September 2024 with $370 million in financing and quickly assembled assets through dealmaking, then lined up a public-market route through Rallybio before attracting a takeout from UCB. That sequence underscores how quickly promising autoimmune platforms can move from startup formation to strategic acquisition when larger companies decide the modality is important enough to own outright. (axios.com)
What to watch: The next milestones are regulatory rather than clinical: antitrust review, formal termination of the Rallybio transaction, and closing sometime around the end of Q2 or start of Q3 2026. After that, the key question is whether UCB keeps Candid’s planned development pace, especially proposed phase 2 expansion for cizutamig, and how quickly it integrates Candid’s pipeline with the ATG-201 program into a coherent autoimmune T-cell engager platform. (pharmexec.com)